To investigate the clinical significance of CDK1‐mediated phosphorylation of TFCP2L1 (p‐TFCP2L1) in BC progression, we used an in‐house polyclonal antibody specific for p‐TFCP2L1 (Appendix Fig S2). Here, TFCP2L1 is linked to breast cancer.